

We claim:

Sub  
C1

1. An immunogenic conjugate molecule comprising hyaluronic acid covalently bound to an immunologically-suitable polypeptide carrier.

Ant  
Cancelled  
06/03/05

2. The immunogenic conjugate according to claim 1, wherein greater than about 50% of the hyaluronic acid molecules possess a nonreducing terminal glucuronic acid and/or unsaturated glucuronic acid residue.

3. The immunogenic conjugate according to claim 2, wherein the hyaluronic acid is a low molecular weight hyaluronic acid with a molecular weight of about 400 Kd or less and a molecular weight of about 600 daltons or more.

4. The immunogenic conjugate according to claim 3, wherein at least 90% or greater of the low molecular weight hyaluronic acid fragments possess a nonreducing terminal glucuronic acid and/or unsaturated glucuronic acid residue.

5. The immunogenic conjugate according to claim 3, wherein at least 95% or greater of the low molecular weight hyaluronic acid fragments possess a nonreducing terminal glucuronic acid and/or unsaturated glucuronic acid residue.

6. The immunogenic conjugate according to claim 3, wherein at least 98% or greater of the low molecular weight hyaluronic acid fragments possess a nonreducing terminal glucuronic acid and/or unsaturated glucuronic acid residue.

7. The immunogenic conjugate according to claim 3, wherein at least 99% or greater of the low molecular weight hyaluronic acid fragments possess a nonreducing terminal glucuronic acid and/or unsaturated glucuronic acid residue.

8. The immunogenic conjugate according to claim 3, wherein the low molecular weight hyaluronic acid is about at least about 4 glycosyl residues in size.

9. The immunogenic conjugate according to claim 3, wherein the low molecular weight hyaluronic acid possess about 2 to about 20 disaccharide subunits.

Sub Q2  
5 10. The immunogenic conjugate according to claim 9, wherein the low molecular weight hyaluronic acid is about 2 to about 10 disaccharide subunits.

11. The immunogenic conjugate according to claim 3, wherein the polypeptide carrier is selected from the group consisting of tetanus toxoid, diphtheria toxoid, pertussis toxoid, an immunogenic polypeptide derived from streptococci, an immunogenic polypeptide derived from influenza, an immunogenic polypeptide derived from meningococci, an immunogenic polypeptide derived from pneumococci, and an immunogenic polypeptide derived from *E. coli*.

12. The immunogenic conjugate according to claim 3, wherein the polypeptide carrier is a porin from neisseria.

15 13. The immunogenic conjugate according to claim 3, wherein the conjugate is directly linked.

Sub Q3  
14. The immunogenic conjugate according to claim 3, wherein the conjugate elicits antibodies that bind an epitope comprising glucuronic acid or unsaturated glucuronic acid (as the) nonreducing terminal sugar of a low molecular weight hyaluronic acid.

20 15. The immunogenic conjugate according to claim 3, wherein the conjugate elicits

antibodies that bind capsular hyaluronic acid present in bacteria.

- Sub 16  
a3

- 5

- 18.

- [illegible]

- 15

- 21.

- 22.

- 20

least about 4 glycosyl residues and no more than about 40 kD in size.

- Sub  
5 Q4
24. A pharmaceutical composition effective for treating or inhibiting group A streptococcal or group C streptococcal infection comprising an antibody selected from the group consisting of an antibody elicited by the composition according to claim 17, an antibody according to 21, or an antibody elicited by low molecular weight hyaluronic acid conjugated to a liposome.
25. A method of eliciting an antibody response in a mammal, said method comprising the step of administering to the individual mammal an amount of a pharmaceutical composition according to claim 17 in an amount which is sufficient to elicit an antibody response.
26. The method according to claim 25, wherein the mammal is a human.
27. The method according to claim 25, wherein the pharmaceutical composition is administered intramuscularly, subcutaneously, intraperitoneally or intravenously.
28. The method according to claim 25, wherein the pharmaceutical composition is administered in an amount of about 0.1 to about 50 micrograms per kilogram body weight.
29. A vaccine that elicits effective levels of anti-low molecular weight hyaluronic acid antibodies in humans comprising the immunogenic conjugate according to claim 3.
- Sub  
Q5
30. A method of inhibiting streptococcal infection in a mammal, comprising administering to the mammal a pharmaceutical composition according to claim 3 in an amount sufficient
- 15
- 20

to inhibit infection.

31. A method of inhibiting progression of infection in a mammal by bacteria containing HA,  
comprising administering to the mammal a composition comprising the pharmaceutical  
composition according to claim 24 in an amount sufficient to inhibit progression of the  
infection.

5

32. The method according to claim 31, wherein the bacteria are group A streptococci or  
group C streptococci.

33. A diagnostic immunoassay kit for detecting infection by streptococci comprising an  
antibody according to claim 21.

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995